JP2022551124A5 - - Google Patents

Info

Publication number
JP2022551124A5
JP2022551124A5 JP2022520901A JP2022520901A JP2022551124A5 JP 2022551124 A5 JP2022551124 A5 JP 2022551124A5 JP 2022520901 A JP2022520901 A JP 2022520901A JP 2022520901 A JP2022520901 A JP 2022520901A JP 2022551124 A5 JP2022551124 A5 JP 2022551124A5
Authority
JP
Japan
Prior art keywords
oligonucleotide
heteroatoms
phosphoramidite
independently
atom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022520901A
Other languages
English (en)
Japanese (ja)
Other versions
JP7766589B2 (ja
JP2022551124A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/054436 external-priority patent/WO2021071858A1/en
Publication of JP2022551124A publication Critical patent/JP2022551124A/ja
Publication of JP2022551124A5 publication Critical patent/JP2022551124A5/ja
Priority to JP2025120874A priority Critical patent/JP2025165976A/ja
Application granted granted Critical
Publication of JP7766589B2 publication Critical patent/JP7766589B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022520901A 2019-10-06 2020-10-06 オリゴヌクレオチド組成物及びその使用方法 Active JP7766589B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025120874A JP2025165976A (ja) 2019-10-06 2025-07-17 オリゴヌクレオチド組成物及びその使用方法

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201962911334P 2019-10-06 2019-10-06
US62/911,334 2019-10-06
US202062959917P 2020-01-11 2020-01-11
US62/959,917 2020-01-11
US202063022559P 2020-05-10 2020-05-10
US63/022,559 2020-05-10
US202063069696P 2020-08-24 2020-08-24
US63/069,696 2020-08-24
PCT/US2020/054436 WO2021071858A1 (en) 2019-10-06 2020-10-06 Oligonucleotide compositions and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025120874A Division JP2025165976A (ja) 2019-10-06 2025-07-17 オリゴヌクレオチド組成物及びその使用方法

Publications (3)

Publication Number Publication Date
JP2022551124A JP2022551124A (ja) 2022-12-07
JP2022551124A5 true JP2022551124A5 (cg-RX-API-DMAC10.html) 2023-10-17
JP7766589B2 JP7766589B2 (ja) 2025-11-10

Family

ID=75437497

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022520901A Active JP7766589B2 (ja) 2019-10-06 2020-10-06 オリゴヌクレオチド組成物及びその使用方法
JP2025120874A Pending JP2025165976A (ja) 2019-10-06 2025-07-17 オリゴヌクレオチド組成物及びその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025120874A Pending JP2025165976A (ja) 2019-10-06 2025-07-17 オリゴヌクレオチド組成物及びその使用方法

Country Status (11)

Country Link
US (1) US20230220384A1 (cg-RX-API-DMAC10.html)
EP (1) EP4022059A4 (cg-RX-API-DMAC10.html)
JP (2) JP7766589B2 (cg-RX-API-DMAC10.html)
KR (1) KR20220076508A (cg-RX-API-DMAC10.html)
CN (1) CN114585737A (cg-RX-API-DMAC10.html)
AU (1) AU2020363391A1 (cg-RX-API-DMAC10.html)
BR (1) BR112022006205A2 (cg-RX-API-DMAC10.html)
CA (1) CA3154768A1 (cg-RX-API-DMAC10.html)
IL (1) IL291933A (cg-RX-API-DMAC10.html)
MX (1) MX2022004101A (cg-RX-API-DMAC10.html)
WO (1) WO2021071858A1 (cg-RX-API-DMAC10.html)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2872147T3 (da) 2012-07-13 2023-02-20 Wave Life Sciences Ltd Fremgangsmåde til fremstilling af kirale oligonukleotider
WO2014010250A1 (en) 2012-07-13 2014-01-16 Chiralgen, Ltd. Asymmetric auxiliary group
EP3094728B1 (en) 2014-01-16 2022-03-09 Wave Life Sciences Ltd. Chiral design
AU2015367378A1 (en) 2014-12-17 2017-06-15 Proqr Therapeutics Ii B.V. Targeted RNA editing
CN117965536A (zh) 2015-07-22 2024-05-03 波涛生命科学有限公司 寡核苷酸组合物及其方法
MA46427A (fr) 2015-10-09 2018-08-15 Wave Life Sciences Ltd Compositions d'oligonucléotides et procédés associés
MA43822A (fr) 2016-03-13 2018-11-28 Wave Life Sciences Ltd Compositions et procédés de synthèse de phosphoramidite et d'oligonucléotides
US11013757B2 (en) 2016-06-03 2021-05-25 Wave Life Sciences Ltd. Oligonucleotides, compositions and methods thereof
EP3475424A1 (en) 2016-06-22 2019-05-01 ProQR Therapeutics II B.V. Single-stranded rna-editing oligonucleotides
WO2018041973A1 (en) 2016-09-01 2018-03-08 Proqr Therapeutics Ii B.V. Chemically modified single-stranded rna-editing oligonucleotides
WO2018098264A1 (en) 2016-11-23 2018-05-31 Wave Life Sciences Ltd. Compositions and methods for phosphoramidite and oligonucleotide synthesis
CA3065523A1 (en) 2017-06-02 2018-12-06 Wave Life Sciences Ltd. Oligonucleotide compositions and methods of use thereof
US11603532B2 (en) 2017-06-02 2023-03-14 Wave Life Sciences Ltd. Oligonucleotide compositions and methods of use thereof
WO2018237194A1 (en) 2017-06-21 2018-12-27 Wave Life Sciences Ltd. Compounds, compositions and methods for synthesis
AU2018316159A1 (en) 2017-08-08 2020-02-06 Wave Life Sciences Ltd. Oligonucleotide compositions and methods thereof
CN111108096A (zh) 2017-09-18 2020-05-05 波涛生命科学有限公司 寡核苷酸制备技术
EP3694530A4 (en) 2017-10-12 2021-06-30 Wave Life Sciences Ltd. COMPOSITIONS OF OLIGONUCLEOTIDES AND RELATED PROCESSES
JP2021521140A (ja) 2018-04-12 2021-08-26 ウェイブ ライフ サイエンシズ リミテッドWave Life Sciences Ltd. オリゴヌクレオチド組成物及びその使用方法
CA3098624A1 (en) 2018-05-11 2019-11-14 Wave Life Sciences Ltd. Oligonucleotide compositions and methods of use thereof
GB201808146D0 (en) 2018-05-18 2018-07-11 Proqr Therapeutics Ii Bv Stereospecific Linkages in RNA Editing Oligonucleotides
AU2020241559A1 (en) 2019-03-20 2021-11-11 Wave Life Sciences Ltd. Technologies useful for oligonucleotide preparation
MX2021012981A (es) 2019-04-25 2022-01-18 Wave Life Sciences Ltd Composiciones de oligonucleotido y metodos de uso de las mismas.
CN115989041A (zh) * 2020-08-24 2023-04-18 波涛生命科学有限公司 经工程化为表达adar1的细胞和非人动物及其用途
JP2023548584A (ja) * 2020-11-08 2023-11-17 ウェイブ ライフ サイエンシズ リミテッド オリゴヌクレオチド組成物及びその方法
WO2023278410A1 (en) * 2021-06-29 2023-01-05 Korro Bio, Inc. Methods and compositions for adar-mediated editing
US20230194709A9 (en) * 2021-06-29 2023-06-22 Seagate Technology Llc Range information detection using coherent pulse sets with selected waveform characteristics
CA3232070A1 (en) * 2021-09-26 2023-03-30 Prashant MONIAN Oligonucleotide compositions and methods thereof
EP4404942A4 (en) * 2021-09-26 2026-06-17 Wave Life Sciences Ltd Compositions for the Editing of Transcripts MECP2 and Related Processes
EP4479535A1 (en) 2022-02-14 2024-12-25 ProQR Therapeutics II B.V. Guide oligonucleotides for nucleic acid editing in the treatment of hypercholesterolemia
WO2023220428A1 (en) * 2022-05-12 2023-11-16 Wave Life Sciences Ltd. Compositions for editing ass1 transcripts and methods thereof
CN119452084A (zh) * 2022-05-12 2025-02-14 波涛生命科学有限公司 寡核苷酸组合物及其方法
EP4555086A1 (en) 2022-07-15 2025-05-21 ProQR Therapeutics II B.V. Oligonucleotides for adar-mediated rna editing and use thereof
EP4555085A1 (en) 2022-07-15 2025-05-21 ProQR Therapeutics II B.V. Chemically modified oligonucleotides for adar-mediated rna editing
EP4558632A1 (en) * 2022-07-18 2025-05-28 F. Hoffmann-La Roche AG Editing oligonucleotide
GB202215614D0 (en) 2022-10-21 2022-12-07 Proqr Therapeutics Ii Bv Heteroduplex rna editing oligonucleotide complexes
KR20250113455A (ko) 2022-11-24 2025-07-25 프로큐알 테라퓨틱스 Ⅱ 비.브이. 유전성 hfe-혈색소침착증의 치료를 위한 안티센스 올리고뉴클레오티드
US20250101418A1 (en) 2022-11-30 2025-03-27 Eberhard-Karls-Universität-Tübingen Chemically modified antisense oligonucleotides (asos) and compositions comprising the same for rna editing
GB202218090D0 (en) 2022-12-01 2023-01-18 Proqr Therapeutics Ii Bv Antisense oligonucleotides for the treatment of aldehyde dehydrogenase 2 deficiency
WO2024121373A1 (en) 2022-12-09 2024-06-13 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of cardiovascular disease
GB202300865D0 (en) 2023-01-20 2023-03-08 Proqr Therapeutics Ii Bv Delivery of oligonucleotides
WO2024175550A1 (en) 2023-02-20 2024-08-29 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of atherosclerotic cardiovascular disease
WO2024175588A1 (en) 2023-02-21 2024-08-29 Vib Vzw Oligonucleotides for modulating synaptogyrin-3 expression
WO2024175586A2 (en) 2023-02-21 2024-08-29 Vib Vzw Inhibitors of synaptogyrin-3 expression
US20250014676A1 (en) 2023-03-15 2025-01-09 Shape Therapeutics Inc. Generative sequence screening with conditional gans, diffusion models, and denoising diffusion conditional gans
JP2026510408A (ja) 2023-03-24 2026-04-02 プロキューアール セラピューティクス ツー ベスローテン フェンノートシャップ 神経障害の処置のためのアンチセンスオリゴヌクレオチド
GB202304363D0 (en) 2023-03-24 2023-05-10 Proqr Therapeutics Ii Bv Chemically modified antisense oligonucleotides for use in RNA editing
EP4688143A1 (en) 2023-03-27 2026-02-11 ProQR Therapeutics II B.V. Antisense oligonucleotides for the treatment of liver disease
WO2024256620A1 (en) 2023-06-16 2024-12-19 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of neurodegenerative disease
AU2024287308A1 (en) 2023-07-13 2025-12-18 Korro Bio, Inc. Rna-editing oligonucleotides and uses thereof
EP4762176A1 (en) 2023-08-15 2026-06-24 Airna Corporation Chemically modified antisense oligonucleotides (asos) and compositions for rna editing
EP4774393A1 (en) 2023-09-07 2026-07-15 ProQR Therapeutics II B.V. Antisense oligonucleotides for the treatment of metabolic disorders
CN122555564A (zh) * 2023-09-28 2026-08-11 波涛生命科学有限公司 寡核苷酸组合物及其方法
WO2025073902A1 (en) 2023-10-06 2025-04-10 Eberhard Karls Universität Tübingen Chemical and sequence optimisation of antisense oligonucleotides for adar-mediated rna editing
WO2025083268A1 (en) 2023-10-20 2025-04-24 Airna Corporation Chemically modified antisense oligonucleotides (asos) and compositions comprising the same for rna editing
WO2025096809A1 (en) 2023-10-31 2025-05-08 Korro Bio, Inc. Oligonucleotides comprising phosphoramidate internucleotide linkages
AU2024379264A1 (en) 2023-11-16 2026-05-14 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of classic galactosemia
WO2025128799A1 (en) 2023-12-12 2025-06-19 Korro Bio, Inc. Double-stranded rna-editing oligonucleotides and uses thereof
AU2024402199A1 (en) 2023-12-20 2026-07-16 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of huntington's disease
WO2025172372A1 (en) 2024-02-12 2025-08-21 Airna Corporation Conjugate for targeted delivery of an antisense oligonucleotide
GB202404661D0 (en) 2024-04-02 2024-05-15 Proqr Therapeutics Ii Bv Antisense oligoncleotides for the treatment of liver disease
WO2025224230A1 (en) 2024-04-25 2025-10-30 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of fatty liver disease
GB202410081D0 (en) 2024-07-11 2024-08-28 Proqr Therapeutics Ii Bv Antisense oligonucleotides for the treatment of cardiovascular disease
WO2026022136A1 (en) 2024-07-23 2026-01-29 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of metabolic disorders
WO2026050243A1 (en) 2024-08-26 2026-03-05 Korro Bio, Inc. Galnac conjugated oligonucleotides for rna editing
WO2026055273A1 (en) * 2024-09-03 2026-03-12 Wave Life Sciences Ltd. Oligonucleotide compositions and methods thereof
WO2026060374A2 (en) 2024-09-16 2026-03-19 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of neurological disorders
WO2026068781A1 (en) 2024-09-30 2026-04-02 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of liver disease
WO2026093339A1 (en) 2024-10-29 2026-05-07 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of peroxisome biogenesis disorders in the zellweger spectrum (pbd-zsd)
WO2026096688A1 (en) * 2024-10-30 2026-05-07 Wave Life Sciences Ltd. Oligonucleotide compositions and methods thereof
WO2026122478A1 (en) 2024-12-02 2026-06-11 Korro Bio, Inc. Extrahepatic delivery formulations and methods
WO2026136663A1 (en) 2024-12-18 2026-06-25 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of neurodegenerative disease

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014169206A2 (en) * 2013-04-11 2014-10-16 Carnegie Mellon University Divalent nucleobase compounds and uses therefor
EP3094728B1 (en) * 2014-01-16 2022-03-09 Wave Life Sciences Ltd. Chiral design
RU2708237C2 (ru) * 2014-08-22 2019-12-05 Общество с ограниченной ответственностью "НооГен" Модифицированные олигонуклеотиды и способ их получения
US10787664B2 (en) * 2015-05-26 2020-09-29 City Of Hope Compounds of chemically modified oligonucleotides and methods of use thereof
MA46427A (fr) * 2015-10-09 2018-08-15 Wave Life Sciences Ltd Compositions d'oligonucléotides et procédés associés
US11013757B2 (en) * 2016-06-03 2021-05-25 Wave Life Sciences Ltd. Oligonucleotides, compositions and methods thereof
WO2018041973A1 (en) * 2016-09-01 2018-03-08 Proqr Therapeutics Ii B.V. Chemically modified single-stranded rna-editing oligonucleotides
WO2018237194A1 (en) * 2017-06-21 2018-12-27 Wave Life Sciences Ltd. Compounds, compositions and methods for synthesis

Similar Documents

Publication Publication Date Title
JP2025041652A5 (cg-RX-API-DMAC10.html)
JP2021074021A5 (cg-RX-API-DMAC10.html)
JP2025165976A5 (cg-RX-API-DMAC10.html)
JP2023548584A5 (cg-RX-API-DMAC10.html)
JP2020522510A5 (cg-RX-API-DMAC10.html)
JP2021529173A5 (cg-RX-API-DMAC10.html)
JP2022535911A5 (cg-RX-API-DMAC10.html)
DE69829760T2 (de) Bi- und tri-zyklische - nukleosid, nukleotid und oligonukleotid-analoga
DE69635744T2 (de) Modifizierte Nukleinsäuresonden
JP2022550915A5 (cg-RX-API-DMAC10.html)
RU2017101172A (ru) Антисмысловые нуклеиновые кислоты
JP2021522803A5 (cg-RX-API-DMAC10.html)
JP3831407B2 (ja) メチルホスホン酸エステル、その製造方法およびその使用
JP2022527569A5 (cg-RX-API-DMAC10.html)
JP2022535735A5 (cg-RX-API-DMAC10.html)
WO2006121820A1 (en) Phosphoramidate prodrugs for treatment of viral infection
JP2021512629A5 (cg-RX-API-DMAC10.html)
JP2019088329A5 (cg-RX-API-DMAC10.html)
JP2020522265A5 (cg-RX-API-DMAC10.html)
PT98931B (pt) Processo para a ligacao de nucleosidos com uma ponte siloxano
CN103980318A (zh) 含有取代苄基的新型核苷磷酸酯前药及其制备方法和用途
CN1118140A (zh) 为提高在酸性pH的稳定性而改性的低聚核苷酸
JP2019503394A5 (cg-RX-API-DMAC10.html)
JP2025516659A5 (cg-RX-API-DMAC10.html)
JPH06220083A (ja) オリゴヌクレオチドとオリゴヌクレオチド類似体の固相合成のための方法と化合物